Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development...

Full description

Bibliographic Details
Main Authors: Elisabeth von Guggenberg, Petra Kolenc, Christof Rottenburger, Renata Mikołajczak, Alicja Hubalewska-Dydejczyk
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
cholecystokinin-2 receptor
agonist
antagonist
tumor targeting
molecular imaging
targeted radiotherapy
Online Access:https://www.mdpi.com/2072-6694/13/22/5776

Internet

https://www.mdpi.com/2072-6694/13/22/5776

Similar Items